18th International Myeloma Workshop - PROGRAM GUIDE SEPTEMBER 8-11, 2021 VIENNA, AUSTRIA - SPARGO, Inc.
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
18th International
Myeloma Workshop
SEPTEMBER 8-11, 2021
VIENNA, AUSTRIA
AND ONLINE
PROG R A M G U I DE
18TH INTERNATIONAL MYELOMA WORKSHOP | 1
18th International
Myeloma Workshop
Principal Organizers
Heinz Ludwig, MD | Chair
Hermann Einsele, MD, FRCP | Co-Chair
Hartmut Goldschmidt, MD, PhD | Co-Chair
Roman Hajek, MD, PhD | Co-Chair
Under the Auspices of the International
Myeloma Society and its Board of Directors
O FFIC ERS
Nikhil C. Munshi, MD | President
Philippe Moreau, MD | Vice-President
María-Victoria Mateos, MD, PhD | Secretary
Shaji Kumar, MD | Treasurer
Jesús San Miguel, MD, PhD | Immediate Past President
BO ARD O F DIRE CTORS
Wee Joo Chng, MD
Vánia Hungria, MD
P. Joy Ho, MBBS
Amrita Krishnan, MD
Giampaolo Merlini, MD
Noopur Raje, MD
Sonja Zweegman, MD, PhD
HO NO RARY BOA RD ME MB E RS
Robert A. Kyle, MD
Kenneth Anderson, MD
Welcome Message
On behalf of the International Myeloma Society, it is our distinct pleasure and honor to welcome you to Vienna
for the 18th International Myeloma Workshop.
Over the past 18 months under extraordinary circumstances, the members of our Scientific Program
Committee have collaborated to create an exceptional program with a wide range of educational
opportunities. Over the next four days, you will have exclusive access to:
140+ expert invited faculty who will present the latest genomic advances, new drug targets and agents,
immunotherapeutic approaches including Car T-cell therapies, COVID-19 in multiple myeloma, and more in
plenary sessions
Nearly 300 oral and poster abstracts to keep you in the forefront of cutting-edge research globally
24 early morning educational sessions held virtually surrounding the management of an aspect of
myeloma and related plasma cell disorders in a small group setting
A host of industry exhibits to provide you with resources and solutions to address your toughest cases
5th Nursing Symposium held virtually targeted for those that provide supportive care for the patient
with multiple myeloma, featuring plenary sessions, oral abstracts, and poster abstract presentations during
this day-long program on Wednesday, September 8
Online access through September 18 to educational content so you can view sessions you may have
missed during the core Workshop dates
3 early morning Career Development Workshops held virtually for fellows and other early-career
hematologists with a focus and interest in multiple myeloma on Thursday, September 9 through Saturday,
September 11
Extended virtual access through December 31 (if purchased during registration) to educational content
so you can view sessions you may have missed during the core Workshop dates
Additionally, recipients of the Society’s top honors will be lauded during the IMS Awards Presentation on
Wednesday, September 8. Further, over 40 IMS Exemplary Abstract Award recipients selected from submitted
abstracts will be honored at the IMS Cultural Celebration and Awards Presentation on Friday, September 10.
Despite our current circumstances, we believe this year’s Workshop will afford you the opportunity to hear the
latest science and innovation, virtually network with colleagues, and learn about practice changing updates
that are ultimately improving the quality of care for our patients around the globe.
Respectfully,
The 18th IMW Principal Organizing Committee,
Heinz Ludwig, MD Hermann Einsele, MD, FRCP
18th IMW Chair 18th IMW Co-Chair
Wilhelminen Cancer Research Institute University Hospital of Würzburg
Vienna, Austria Würzburg, Germany
Hartmut Goldschmidt, MD, PhD Roman Hajek, MD, PhD
18th IMW Co-Chair 18th IMW Co-Chair
University Hospital Heidelberg University Hospital Ostrava
Heidelberg, Germany Ostrava, Czech Republic
18TH INTERNATIONAL MYELOMA WORKSHOP | 1
Schedule-at-a-Glance
WEDNESDAY, SEPTEMBER 8 THURSDAY, SEPTEMBER 9
(V) Meet the Expert Sessions
(V) Career Development Workshop
08:00-09:00
08:00-09:00
Welcome to the 18th IMW Opening Session
09:00-09:30 09:00-09:30
09:00-10:00
IMS President Address Newly Diagnosed Multiple
09:30-10:00 Myeloma: Current Treatment
Precursor Conditions Approaches
10:00-11:15 09:30-10:30
10:00-11:00
Oral Abstract Sessions
(B1 and C1)
Molecular dissection of myeloma
11:00-12:00 10:30-11:45
11:15-12:30
10:30-16:50 | (V) 5th Nursing Symposium
Management of Relapsed/
09:00 -19:00 | Poster Session Viewing Hours
Lunch in Exhibit Hall Refractory MM Patients
12:00-13:00 12:30-13:30 11:45-12:45
Lunch in Exhibit Hall
12:00-17:00 | Exhibition Hall Open
Multiple Myeloma Diagnosis 12:45-13:45
13:00-14:00 13:30-14:30
Industry Sponsored Symposium
12:00-19:15 | Exhibition Hall Open
IMS Awards 13:45-15:15
14:00-15:00 14:30-15:15
15:00-16:00 Break in the Exhibition Hall 15:15- Oral Abstract Sessions
15:45 (B2 and C2)
15:15-16:30
Industry Sponsored Symposium
15:45-16:45 Break in the Exhibition Hall
16:00-17:00 16:30-17:00
Hot Topics Industry Sponsored Symposium
16:45-17:45 17:00-18:00
17:00-18:00
Welcome Reception in the
Poster Session Presentations and
Exhibition Hall
Reception
18:00-19:00 17:45-19:15
18:00-19:00
(V) = virtual-only session | (B) = Biology abstract session | (C) = Clinical abstract session
2 | 18TH INTERNATIONAL MYELOMA WORKSHOP
All times listed and events, including virtual-only sessions, are
being held in Central European Standard Time.
FRIDAY, SEPTEMBER 10 SATURDAY, SEPTEMBER 11
(V) Meet the Expert Sessions (V) Meet the Expert Sessions
(V) Career Development Workshop (V) Career Development Workshop
08:00-09:00
08:00-09:00 08:00-09:00
Opening Session Industry Sponsored Symposium
09:00-09:30 09:00-10:00
09:00-10:00
IMS/EHA Symposium
09:30-10:30 Oral Abstract Sessions
(B5 and C5)
10:00-11:00
10:00-11:15
Oral Abstract Sessions
(B3 and C3)
10:30-11:45 11:00-12:00
Great Debates in Myeloma
11:15-13:15
Other Plasma Cell Disorders
09:00 -19:00 | Poster Session Viewing Hours
11:45-12:45
12:00-13:00
Lunch in Exhibit Hall
12:45-13:45 Lunch in Foyer
13:15-13:45 13:00-14:00
Industry Sponsored Symposium Supportive Care Management
12:00-19:15 | Exhibition Hall Open
13:45-15:15 13:45-14:45
14:00-15:00
Immune Therapies
Oral Abstract Sessions 14:45-15:45
(B4 and C4) 15:00-16:00
15:15-16:30
Clinical Trials in Progress
15:45-16:45
Break in the Exhibition Hall 16:00-17:00
16:30-17:00 Welcome to the 19th IMW
16:45-16:55
Industry Sponsored Symposium Closing Comments
17:00-18:00 16:55-17:00
17:00-18:00
Hot Topics in Myeloma:
COVID-19 in Multiple Myeloma:
18:00-19:00
What Have We Learnt?
18:00-19:00
(V) = virtual-only session | (B) = Biology abstract session | (C) = Clinical abstract session
18TH INTERNATIONAL MYELOMA WORKSHOP | 3
Invited Faculty
Virginia Abello, MD Fundación Universitaria de Ciencias de la Salud Bogotá, Colombia
Rafat Abonour, Professor Indiana University School of Medicine Indianapolis, IN
United States
Sikander Ailawadhi, MD Mayo Clinic Jacksonville, FL
United States
Melissa Alsina, MD Moffitt Cancer Center Tampa, FL
United States
Kenneth C. Anderson, MD Harvard Medical School and Boston, MA
Dana-Farber Cancer Institute United States
Daniel Auclair, PhD Multiple Myeloma Research Foundation Norwalk, CN
United States
Herve Avet-Loiseau, MD, PhD IUC-Oncopole Toulouse, France
David Avigan, MD Beth Israel Deaconess Medical Center Boston, MA
United States
Nizar Bahlis, MD University of Calgary Calgary, AB, Canada
Meral Beksac, MD Ankara University Ankara, Turkey
William Bensinger, MD Swedish Cancer Institute Seattle, WA
United States
Leif Bergsagel, MD Mayo Clinic Scottsdale, AZ
United States
Manoj Bhasin, PhD Emory University Atlanta, GA
United States
Joan Blade Creixentí, MD, PhD Hospital Clínic de Barcelona (ICMHO) Barcelona, Spain
Mario Boccadoro, MD European Myeloma Network Italy
Lawrence Boise, PhD Emory University Atlanta, GA
United States
Niccolo Bolli, MD, PhD University of Milan Milan, Italy
Ivan Borrello, MD Johns Hopkins University Baltimore, MD
United States
Annemeik Broyl, MD, PhD Erasmus University Medical Center Rotterdam,
Netherlands
Mark Bustoros, MD Meyer Cancer Center, Weill Cornell Medicine, New York, NY
Cornell University United States
Natalie S. Callander, MD University of Wisconsin Carbone Cancer Center Madison, WI
United States
4 | 18TH INTERNATIONAL MYELOMA WORKSHOP
Ruben Carrasco, MD, PhD Harvard Medical School Boston, MA
United States
Michele Cavo, MD, PhD “Seràgnoli” Institute of Haematology - Bologna Bologna, Emilia-
University School of Medicine - IRCCS S.Orsola- Romagna, Italy
Malpighi
Ajai Chari, MD Mount Sinai New York, NY
United States
Dharminder Chauhan, PhD Dana-Farber Cancer Institute Boston, MA
United States
Wenming Chen, MD, PhD Multiple Myeloma Research Center of Beijing Beijing, China
Marta Chesi, PhD Mayo Clinic Scottsdale, AZ
United States
Wee Joo Chng, MB ChB, PhD National University Cancer Institute, Singapore Singapore
Hearn J. Cho, MD, PhD Tisch Cancer Institute, Icahn School of Medicine New York, NY
at Mt. Sinai United States
Adam D. Cohen, MD University of Pennsylvania Philadelphia, PA
United States
Craig Emmitt Cole, MD Michigan State University College of Human East Lansing, MI
Medicine United States
Raymond Comenzo, MD Tufts Medical Center Boston, MA
United States
Gordon Cook, Professor University of Leeds and National Institute of Leeds, United Kingdom
Health Research
Jill Corre, Medical Biologist IUCT-O Toulouse, France
Luciano J. Costa, MD, PhD University of Alabama at Birmingham Vestavia, AL
United States
Faith Davies, MD, MBBCh, MRCP, NYU Langone Health Perlmutter Cancer Center New York, NY
FRCPath United States
Javier de la Rubia, PhD, MD University Hospital La Fe. School of Medicine Valencia, Spain
and Dentistry, Catholic University of Valencia,
Valencia, Spain
Ruth De Tute, PhD Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom
Michel Delforge, MD, PhD University of Leuven Leuven, Belgium
Madhav Dhodapkar, MBBS Emory University School of Medicine Atlanta, GA
United States
Meletios-Athanassios National and Kapodistrian University of Athens, Athens, Greece
Dimopoulos, MD Alexandra Hospital, School of Medicine
Angela Dispenzieri, MD Mayo Clinic Rochester, MN
United States
Matthew Drake, MD, PhD Mayo Clinic College of Medicine Rochester, MN
United States
18TH INTERNATIONAL MYELOMA WORKSHOP | 5
Invited Faculty (cont.)
Juan Du, PhD, MD Shanghai Changzheng hospital Shanghai, Republic of
China
Brian GM Durie, MD International Myeloma Foundation North Hollywood, CA
United States
Hermann Einsele, MD, FRCP University Hospital Würzburg Würzburg, Germany
Thierry Facon, MD Lille University Hospital Lille, France
Dorotea Fantl, MD Hospital Italiano de Buenos Aires Buenos Aires,
Argentina
Jean-Paul Fermand, MD Paris VII University Paris, France
Rafael Fonseca, MD Mayo Clinic Arizona Paradise Valley, AZ
United States
Mariateresa Fulciniti, PhD Dana-Farber Cancer Institute Boston, MA
United States
Gösta Gahrton, MD, PhD Karolinska Institutet, Department of Medicine Stockholm, Sweden
Ramon Garcia-Sanz, MD, PhD University Hospital of Salamanca Salamanca, Spain
Laurent Garderet, MD Sorbonne Université, APHP Paris, France
Moshe Gatt, MD Hadassah Hebrew University Medical Center Jerusalem, Israel
Morie A. Gertz, MD Mayo Clinic Rochester, MN
United States
Irene Ghobrial, MD Dana-Farber Cancer Institute/Harvard Medical Boston, MA
School United States
Sergio Giralt, MD. FACP, FASTCT Memorial Sloan Kettering Cancer Center New York, NY
United States
Harmut Goldschmidt, MD Medical Department V, Heidelberg University Heidelberg, Germany
Clinic and National Center of Tumor Diseases
(NCT) in Heidelberg.
Wilson I. Gonsalves, MD Mayo Clinic Rochester, MN
United States
Roman Hajek, MD, PhD University Hospital Ostrava nad University of Ostrava, Czech
Ostrava Republic
Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI
United States
Jean-Luc Harousseau, MD INSTITUT DE CANCEROLOGIE DE L’OUEST Saint Herblain, France
FRANCE
Simon J. Harrison, MBBS, MRCP, Peter MacCallum Cancer Centre Melbourne, Victoria,
FRCPath, FRACP, PhD Australia
Matthias Hellberg-Naegele, MSc Comprehensive Cancer Center Zurich Haigerloch, Germany
Jens Hillengass, MD, PhD Roswell Park Comprehensive Cancer Center Buffalo, NY
United States
P. Joy Ho, MBBS, DPhil, FRACP, Institute of Haematology, Royal Prince Alfred Camperdown, New
FRCPA Hospital South Wales, Australia
6 | 18TH INTERNATIONAL MYELOMA WORKSHOP
Sarah A. Holstein, MD, PhD University of Nebraska Medical Center Omaha, NE
United States
Jeffrey SY Huang, PhD National Taiwan University and Hospital Taipei, Taiwan
(Republic of China)
Michael Hudecek, MD Universitätsklinikum Würzburg, Department of Würzburg, Germany
Internal Medicine II
Vania Hungria, MD, PhD Clinic Sao Germano Sao Paulo, Brazil
Graham Jackson, MD, PhD Northern Centre for Cancer Care Newcastle, United
Kingdom
Sundar Jagannath, MBBS Mount Sinai Hospital Long Island City, NY
United States
Andrzej Jakubowiak, MD, PhD University of Chicago Chicago, IL
United States
Diane F. Jelinek, PhD Mayo Clinic Scottsdale, AZ
United States
Tomas Jelinek, MD University Hospital Ostrava Ostrava, Czech
Republic
Douglas E. Joshua, Professor University of Sydney Sydney, Australia
Artur Jurczyszyn, MD, PhD Plasma Cell Dyscrasia Center Jagiellonian Kraków, Poland
University Department of Hematology Kraków
Poland
Martin Kaiser, MD Royal Marsden Hospital London, United
Kingdom
Prashant Kapoor, MD Mayo Clinic Rochester, MN
United States
Efstathios Kastritis, MD, PhD National and Kapodistrian University of Athens, Athens, Greece
School of Medicine
Jonathan Kaufman, MD Winship Cancer Institute Atlanta, GA
United States
Jonathan J. Keats, PhD TGen - City of Hope Phoenix, AZ
United States
Taxiarchis Kourelis, MD Mayo Clinic Rochester, MN
United States
Maria-Theresa Krauth, MD Medical University of Vienna Vienna, Austria
Sigurdur Y. Kristinson, MD, PhD University of Iceland Reykjavik, Iceland
Shaji K. Kumar, MD Mayo Clinic Rochester, MN
United States
Ola Landgren, MD, PhD Sylvester Comprehensive Cancer Center, Miami, FL
University of Miami United States
Alessandra Larocca, MD, PhD Division of Hematology, University of Torino, Torino, Italy
Azienda Ospedaliero-Universitaria Città della
Salute e della Scienza di Torino
18TH INTERNATIONAL MYELOMA WORKSHOP | 7
Invited Faculty (cont.)
Jacob Laubach, MD Dana-Farber Cancer Institute Boston, MA
United States
Merav Leiba, MD Assuta University Hospital Ashdod, Israel
Xavier Leleu, MD CHU la Miletrie Poitiers, France
Suzanne Lentzsch, MD, PhD Columbia University Medical Center New York, NY
United States
Nelson Leung, MD Mayo Clinic Rochester, MN
United States
Yi Lin, MD, PhD Mayo Clinic Rochester Rochester, MN
United States
Jens Lohr, MD, PhD Dana-Farber Cancer Institute Boston, MA
United States
Sagar Lonial, MD Emory University Atlanta, GA
United States
Heinz Ludwig, MD Wilhelminen Cancer Research Institute Vienna, Austria
Sham Mailankody, MBBS Memorial Sloan Kettering Cancer Center New York, NY
United States
Angelo Maiolino, MD, PhD Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil
Pankaj Malhotra, MD Postgraduate Institute of Medical Education and Chandigarh, India
Research
Elisabet Manasanch, MD, MHSc MD Anderson Cancer Center Houston, TX
United States
Saloman Manier, MD, PhD Lille University Hospital Lille, France
Tom Martin, MD UCSF Helen Diller Family Comprehensive Cancer San Francisco, CA
Center United States
Joaquin Martinez, MD, PhD Universitario 12 de Octubre Madrid, Spain
María-Victoria Mateos, MD, PhD University Hospital of Salamanca Salamanca, Spain
Philip l. McCarthy, MD Roswell Park Comprehensive Cancer Center Williamsville, NY
United States
Giampaolo Merlini, MD IRCCS Polkiclinico San Matteo, Pavia Pavia, Italy
Constantine Mitsiades, MD Dana-Farber Cancer Institute Boston, MA
United States
Mohamad Mohty, MD, PhD Saint-Antoine Hospital and Sorbonne University Paris, France
Philippe Moreau, MD CHU de Nantes, University Hospital Hôtel-Dieu- Nantes, France
HME
Gareth Morgan, MBBCh, PhD, NYU Langone Health Perlmutter Cancer Center New York, NY
FRCP, FRCPath United States
Eli Muchtar, MD Mayo Clinic Rochester, MN
United States
Nikhil Munshi, MD Dana-Farber Cancer Institute, Harvard Medical Boston, MA
School United States
8 | 18TH INTERNATIONAL MYELOMA WORKSHOPDavid Murray, MD, PhD Mayo Clinic Rochester, MN
United States
Hareth Nahi, Professor Karolinska Institutet Solna, Sweden
Paola Neri, MD, PhD University of Calgary Calgary, AB, Canada
Ruben Niesvizky, MD Weill Cornell Medicine/New York-Presbyterian New York, NY
Hospital United States
Ajay K. Nooka, MD, MPH Winship Cancer Institute of Emory University Atlanta, GA
United States
Enrique M. Ocio, MD, PhD University Hospital Marqués de Valdecilla Santander, Spain
(IDIVAL). University of Cantabria
Elizabeth O'Donnell, MD Massachusetts General Hospital Boston, MA
United States
Michael O'Dwyer, MD National University of Ireland, Galway Galway, Ireland
Bob Orlowski, MD, PhD The University of Texas MD Anderson Cancer Houston , TX
Center United States
Bruno Paiva, PhD Clinica Universidad de Navarra Pamplona, Spain
Giovanni Palladini, MD, PhD University of Pavia Pavia, Italy
Krina Patel, MD UT MD Anderson Cancer Center Houston , Texas
United States
Charlotte Pawlyn, MB BChir, The Institute of Cancer Research / The Royal Sutton, England
PhD, MRCP, FRCPath Marsden Hospital
Aurore Perrot, MD, PhD University of Toulouse, IUCT Oncopole Toulouse, France
Rashek Popat, MD, PhD University College Hospital London, United
Kingdom
Noemi Puig, MD, PhD University Hospital of Salamanca Salamanca, Spain
Lugui Qiu, MD Institute of Hematology and Blood Diseases Tianjin, China
Hospital, Chinese Academy of Medical Sciences (People's Republic)
Hang Quach, MD St.Vincent’s Hospital Melbourne Fitzroy, Australia
Marc-Steffen Raab, MD University Hospital Heidelberg Heidelberg, Germany
Jakub Radocha, MD, PhD University Hospital Hradec Kralove Hradec Kralove,
Kralovehradecky kraj,
Czech Republic
Noopur Raje, MD Massachusetts General Hospital Boston, MA
United States
S. Vincent Rajkumar, MD Mayo Clinic Rochester, MN
United States
Karthik Ramasamy, PhD Oxford University Hospitals NHS Foundation Oxford, United
Trust Kingdom
Donna Reece, MD University Health Network, Princess Margaret Toronto, ON, Canada
Cancer Centre
18TH INTERNATIONAL MYELOMA WORKSHOP | 9Invited Faculty (cont.)
Paul Richardson, MD Dana Farber Cancer Institute Boston, MA
United States
Paula Rodriguez, MD University of Navarra Pamplona, Spain
Laura Rosiñol, MD, PhD Hospital Clinic of Barcelona Barcelona, Spain
Mehmet Samur, PhD Dana Farber Cancer Institute Boston, MA
United States
Vaishali Sanchorawala, MD Boston University School of Medicine & Boston Boston, MA
Medical Center United States
Jesus San-Miguel, PhD, MD Universidad de Navarra/Clínica Universidad de Pamplona, Spain
Navarra
Fredrik Schjesvold, MD Oslo Myeloma Center Olso, Norway
Nina Shah, MD University of California San Francisco San Francisco, CA
United States
Masood A. Shammas, PhD Harvard (Dana Farber) Cancer Institute Boston, MA
United States
Malathy Shanmugam, MS, PhD Winship Cancer Institute, Emory University Atlanta, GA
United States
Pieter Sonneveld, MD, PhD Erasmus MC Rotterdam,
Netherlands
Adam S. Sperling, MD, PhD Brigham and Women’s Hospital Boston, MA
United States
Edward Stadtmauer, MD University of Pennsylvania Bryn Mawr, PA
United States
Keith Stewart, MD Princess Margaret Cancer Centre Toronto, ON, Canada
Evangelos Terpos, MD, PhD National and Kapodistrian University of Athens, Athens, Greece
School of Medicine, Athens, Greece
Rodger Tiedeman, PhD Princess Margaret Cancer Centre Toronto, ON, Canada
Cyrille Touzeau, MD, PhD University Hospital Nantes Nantes, France
Steve Treon, MD, PhD, FACP, Dana Farber Cancer Institute Boston, MA
FRCP United States
Suzanne Trudel, MD, MSc Princess Margaret Cancer Centre Toronto, ON, Canada
Saad Z. Usmani, MD, MBA, FACP Levine Cancer Institute Charlotte, NC
United States
Neils van de Donk, MD, PhD VU University Medical Center Amsterdam,
Netherlands
Karin Vanderkerken, PhD Vrije Universiteit Brussel (VUB) Brussels, Belgium
Ravi Vij, MD, MBA Washington University School of Medicine Ballwin, MO
United States
Peter Voorhees, MD Levine Cancer Institute, Atrium Health Charlotte, NC
United States
10 | 18TH INTERNATIONAL MYELOMA WORKSHOPBrian A. Walker, PhD Indiana University Indianapolis, IN
United States
Niels Weinhold, PhD University of Heidelberg Heidelberg, Germany
Katja Weisel, MD University Cancer Center Hamburg, University Hamburg, Germany
Medical Center Hamburg-Eppendorf
Arun P. Wiita, MD, PhD University of California, San Francisco San Francisco, CA
United States
Jeffrey L. Wolf, MD University of California, San Francisco (UCSF) San Francisco, CA
United States
Qing Yi, MD, PhD Houston Methodist Cancer Center Houston, TX
United States
Kwee Yong, Professor University College London London, United
Kingdom
Elena Zamagni, MD Bologna University School of Medicine Bologna, Italy
Niklas Zojer, Priv Doz Dr Klinik Ottakring, Vienna Vienna, Austria
Photo/Audio Recording Policy
The presentations, slides and handouts provided Workshop may be used in future IMS and IMW
during the program are the property of the IMS materials.
or used with permission. Delegates may not
photograph, videotape, audiotape or otherwise VI DE O T A P I N G
record or reproduce any of the presentations Videotaping or live streaming in any poster session
without express written permission from the IMS, or session room is strictly prohibited.
presenter, or copyright owner of such materials.
A U DI O R E CO R DI N G
D I S C LAIMER Audio recording or live audio in any poster session
The IMW will have a professional photographer or session room is strictly prohibited, except by
present at the Workshop. Therefore, please note registered members of the media.
that any photographs and video taken at the
18TH INTERNATIONAL MYELOMA WORKSHOP | 11ABO UT THE
The International Myeloma Society (IMS) is a professional, scientific,
and medical society established to bring together clinical and
experimental scientists involved in the study of myeloma.
The IMS is a membership organization comprised of basic research
scientists, and clinical investigators in the field along with physicians
and other healthcare practitioners. The IMS is governed by a Board of
Directors representing practices from around the world, encouraging
and promoting the study of this expanding field.
Thousands of the world’s key opinion leaders in the field of myeloma
gather together at the International Myeloma Workshop which includes
Scientific Programs, Oral Presentations (on Basic Biology, Preclinical
Trials and Clinical Studies), Consensus Panels and Poster Presentations.
IMS Educational Workshops, smaller and more intimate meetings, are
designed to address more regional and local topics and needs. These
workshops are held in cities throughout the world and virtually. Past
programs have been held in Latin America, Europe and the US.
Become an IMS member today by visiting myelomasociety.org or
visiting the IMS Stand #111 during the dedicated exhibition hours.
12 | 18TH INTERNATIONAL MYELOMA WORKSHOPScientific Information
Abstracts Accreditation Statement
Abstracts are available electronically through the In support of improving patient care, this activity
www.imw2021vienna.org website and through the has been planned and implemented by Amedco LLC
18th IMW mobile app. All abstracts are numbered to and International Myeloma Society (IMS). Amedco
correspond with presentations listed in this program LLC is jointly accredited by the Accreditation Council
guide. for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE),
Conflict of Information Policy and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the
healthcare team.
The goals of the IMW are to facilitate improved
knowledge and understanding of appropriate, P H Y S I CI A N S (A CCM E ) CR E DI T
personalized therapeutic strategies for assessing DE S I G N A T I O N
and caring for patients for multiple myeloma. The Amedco LLC designates this live activity /
IMW has a fundamental interest in ensuring that its enduring material for a maximum of 27.75
educational content is consistent with these goals. live / 27.75 enduring AMA PRA Category 1
Credits™. Physicians should claim only the
In accordance with the ACCME, all workshop co-
credit commensurate with the extent of their
chairs, session chairs, speakers and oral abstract
participation in the activity.
presenters are required to disclose any conflicts they
may have in writing prior to the meeting. All IMW I N T E R N A T I O N A L CM E A CCR ED I T A T I ON
presenters (including workshop co-chairs and session The American Medical Association has
chairs) are asked to disclose to the audience any determined that physicians not licensed in the US
relationships of the following nature: compensated who participate in this CME activity are eligible for
employment, leadership position, consulting activity, AMA PRA Category 1 Credits™. ACCME / AMA PRA
speaking engagement, equity ownership, grant/ Category 1 Credits™ carry reciprocity with EACCME
research support, patents or other intellectual member countries and most international
property interests, and, in some instances, being licensing bodies for physicians, with some
an official representative of another organization. exceptions. Physicians should check with their
All poster presenters are required to disclose any country/board for eligibility.
conflicts they may have in writing prior to the meeting N U R S E S (A N CC) CR E DI T DE S I G N A T I ON
and display their disclosures on their poster.
Amedco LLC designates this activity for a
Any questions about this policy or concerns regarding maximum of 27.75 live / 27.75 enduring ANCC
disclosures should be directed to the Registration contact hours.
desk in Foyer A.Scientific Information (cont.)
How to Claim Credit/ Posters
Certificate of Attendance Virtual posters can be accessed through the online
virtual platform accessible through imw2021vienna.org.
AMA PRA and ANCC contact hours must be claimed
online. Visit imw2021vienna.org for access.
Certificates of attendance can also be accessed through Virtual Access
imw2021vienna.org. You will need the email address
used to register for the Workshop and your six-digit Depending upon your registration package, two
registration ID (located on your badge). virtual access options exist:
You must claim credit by January 31, 2022. Online access through September 18, 2021
Extended online access through
Language December 31, 2021
Livestreamed sessions will be available for on-
The official language of the IMW is English, with no demand viewing in the platform typically within
simultaneous translation into other languages. 24 hours of their original broadcast unless editing
or redaction is required. Virtual-only sessions are
Mobile App indicated in the daily program schedule.
To access the virtual platform, visit imw2021vienna.org.
Download the International Myeloma Society mobile To log in, you will need the email address used to
app from the App Store or Google Play. The IMS register and your six-digit registration ID located on
mobile app allows you to access complete 18th IMW your badge.
information at your fingertips. Be sure to download
the app on your phone or tablet for one-touch access
to the following: Workshop Updates
Poster and oral abstracts Parts of the program may be changed without prior
Interactive schedule including the ability to create notice. Please refer to the Workshop mobile app for
your own schedule and take notes during sessions the most current schedule and speaker information.
Up-to-the-minute Workshop updates
Messaging capabilities with other attendees who
have downloaded the app and created a profile
Faculty listing
Sponsor and exhibitor listings
Meeting venue map
14 | 18TH INTERNATIONAL MYELOMA WORKSHOPJoin the Bristol Myers Squibb Satellite Symposium
at the 18th International Myeloma Workshop 2021
New Era of Immune
Therapies in Multiple Myeloma
Friday, 10 September 2021 | 13:45–15:15 CEST
Add to my calendar
MESSE WIEN Exhibition & Congress Center,
Vienna, Austria | Hall A7–A8
13:45–13:50 Welcome and introduction
Noopur Raje
Massachusetts General Hospital, Boston, MA, USA
13:50–14:00 Cereblon E3 ligase as a therapeutic mediator for protein degradation
Nizar J. Bahlis
Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
14:00–14:15 Early clinical data on cereblon E3 ligase modulators
Sagar Lonial
Winship Cancer Institute of Emory University, Atlanta, GA, USA
14:15–14:35 Clinical evidence for CAR T cell therapy in multiple myeloma
Nina Shah
University of California San Francisco, San Francisco, CA, USA
14:35–14:50 The future of cellular and immune therapies in multiple myeloma
Noopur Raje
Massachusetts General Hospital, Boston, MA, USA
14:50–15:15 Discussion and Q&A
All faculty
This symposium is restricted to healthcare professionals only © 2021 Bristol-Myers Squibb Company
This symposium is sponsored by Celgene, a Bristol-Myers Squibb Company NP-WWM-IDE-0163 08/21Network with Friends,
Colleagues, and Future
Collaborators
In addition to four days of exceptional education, the 18th IMW will offer plenty of opportunities for
participants to come together and be inspired by friends, colleagues, and future collaborators. You will enjoy
time to network between sessions and in the evening at the following events:
Wednesday, September 8 Friday, September 10
WE L C O ME RECE PTION I M S CU L T U R A L CE L E B R A T I O N A N D
A W A R DS P R E S E N T A T I O N
17:45-19:15
Exhibition Hall, Hall A 20:00-23:00
The Hofburg
Join us in the exhibition hall for our welcome
reception. Network with fellow attendees and Join us for an evening celebration featuring the
visit with exhibitors to learn more about the latest culinary and cultural highlights of Vienna and Austria
innovations in multiple myeloma. as well as the presentation of the Exemplary Abstract
Awards to over 40 promising myeloma researchers
whose abstracts were accepted for oral or poster
presentation at the IMW.
Shuttle service will be provided between all official IMW
hotels and the Hofburg beginning at 19:45.
16 | 18TH INTERNATIONAL MYELOMA WORKSHOPJOIN US ON HME-forum.com
Please scan here
to register for the
Myeloma
upcoming webinars
Connect 2021
Myeloma Connect 2021 is a series of live,
interactive broadcasts, each focusing on
a specific topic relevant to hemaatologists
treating patients with multiple myeloma.
Register your interest at: www.HME-forum.com
Registered participants will also be able to view archived versions of
Myeloma Connect the broadcasts following the live events.
Scientific
Committee: SEPTEMBER 2021
18.00–18.45 CEST, 16 September 2021
How can we identify the most appropriate
cellular therapy for each patient?
Moderator: Mohamad Mohty, France
Faculty: Paula Rodríguez-Otero, Spain
18.00–18.45 CEST, 23 September 2021
Michel Delforge Addressing the challenge of frail patients with MM
BELGIUM Moderator: Mohamad Mohty, France
Faculty: Salomon Manier, France
OCTOBER 2021
18.00–18.45 CEST, 7 October 2021
What is the role of tandem transplantation in 2021?
Moderator: Mohamad Mohty, France
Faculty: Niels van de Donk, The Netherlands
Mohamad Mohty
FRANCE 18.00–18.45 CEST, 26 October 2021
Smoldering MM – to treat or not to treat?
Moderator: Michel Delforge, Belgium
REGISTER AT
Faculty: María-Victoria Mateos, Spain
www.HME-forum.com/register
Please note that all events are open only to healthcare professionals.
Registration prior to the live event is required in order to access both
the live and archived broadcasts.
Depending on your country, you may not have access to HME Forum.
Organized and supported by Janssen Pharmaceutical
Companies of Johnson & Johnson in EMEA EM-69389
Janssen Pharmaceutica NV Date of preparation: August 2021
Turnhoutseweg 30 Copyright © 2021 Janssen
2340 Beerse, Belgium Pharmaceutica NVIMS Award Recipients
THE INTERNATIONAL MYELOMA SOCIETY IS PLEASED TO RECOGNIZE THE FOLLOWING
Join us on
Wednesday, Waldenström Award
September 8 at
S. VI N CE N T R A JKU M A R , M D
14:30 for the formal
Mayo Clinic
recognition of all IMS
Rochester, United States
award recipients.
The Waldenström Award has been given by the IMS at each International
Myeloma Workshop since 1989. This award is given to outstanding researchers in
recognition of their contributions to the myeloma field. The award is named for
Professor Jan Waldenström, who was a pioneer in treating blood cancers.
Bart Barlogie Young Investigator Award
SA A D U S M A N I , M D
Levine Cancer Institute/Carolinas Healthcare System
Charlotte, United States
In recognition to the outstanding research developed by Dr. Bart Barlogie in
the field of multiple myeloma, the IMS established the Bart Barlogie Young
Investigator Award. The Bart Barlogie Young Investigator Award is given to an
investigator under the age of 45 years to both recognize and stimulate excellence
in myeloma research.
Ken Anderson Young Investigator Award
E. P A O L A N E R I , P H D, M D
University of Calgary, Arnie Charbonneau Cancer Institute
Calgary, Canada
Established by the IMS to honor the seminal contributions of Dr. Ken Anderson
from bench to bedside translational research, the Ken Anderson Young
Investigator Award is given to an investigator under the age of 45 to both
recognize and stimulate excellence in myeloma research.
18 | 18TH INTERNATIONAL MYELOMA WORKSHOPIMS Exemplary Abstract Award Recipients
THE IMS IS PLEASED TO WELCOME THE FOLLOWING YOUNG
INVESTIGATORS TO THE IMW TO PRESENT THEIR RESEARCH:
Hasan Yalim Akin Kareem Midlig
Erman Akkus Brittany Miles
Silvia Armuzzi Eugenio Morelli
Sarah Bird David Moreno
Sotirios Bristogiannis Maria Moscvin
Carlos Castillo-Girón Tyler Moser-Katz
Wei Yee Chan Aina Oliver Caldés
Zuzana Chyra Alexis Phillips
Olga Czerwińska-Ledwig Andrea Poletti
Mattia D’Agostino Afsaneh Shariatpanahi
Sophia Danhof Romanos Sklavenitis-Pistofidis
Madelon de Jong Antonio Solimando
A. Cathelijne Fokkema Vincenza Solli
Nico Gagelmann Virág Szita
David Garrido Sabrin Tahri
Lixin Gong Santiago Thibaud
Annamaria Gulla Natthakan Thongon
Lukas John Hideki Uryu
Chengcheng Liao Oliver Van Oekelen
Kenneth Lim Alissa Visram
Angelica Macauda Xiaojing Wei
Elias Mai Sinan Xiong
Elena Maroto Martín Yuting Yan
Marina Martello Wei Yan
Gaia Mazzocchetti
Nikita Mehra
18TH INTERNATIONAL MYELOMA WORKSHOP | 19FORGE AHEAD
WITH A BOLD APPROACH FACHKURZINFORMATION
BLENREP 100 mg Pulver für ein Konzentrat zur
Herstellung einer Infusionslösung; Qualitative und
Quantitative Zusammensetzung: Eine Durchstechflasche
Visit us on-site at Booth #603 mit Pulver enthält 100 mg Belantamab-Mafodotin.
Nach der Rekonstitution enthält die Lösung 50 mg
to learn more about BLENREP
Belantamab-Mafodotin pro ml. Belantamab-Mafodotin
ist ein Antikörper-Wirkstoff-Konjugat aus dem gegen
das B-Zell-Reifungsantigen (B cell maturation antigen
= BCMA) spezifischen, afucosylierten, humanisierten,
BLENREP is the first anti-BCMA ADC that delivers direct cytotoxicity and induces
monoklonalen IgG1k-Antikörper Belantamab, der
immune responses for appropriate patients with RRMM.1
mittels rekombinanter DNA-Technologie in einer
Säugerzelllinie (Ovarialzellen des chinesischen Hamsters)
hergestellt wird und der mit Maleimidocaproyl-
Monomethyl-Auristatin F (mcMMAF) konjugiert ist.
Sonstige Bestandteile: Natriumcitrat, Zitronensäure,
Trehalose-Dihydrat, Dinatriumedetat, Polysorbat 80;
Pharmakotherapeutische Gruppe: Antineoplastika,
monoklonale Antikörper, ATC-Code: L01XC39.
Anwendungsgebiete: BLENREP ist indiziert als
Monotherapie zur Behandlung des multiplen Myeloms
bei erwachsenen Patienten, die bereits mindestens vier
Therapien erhalten haben und deren Erkrankung refraktär
gegenüber mindestens einem Proteasom-Inhibitor, einem
Immunmodulator und einem monoklonalen Anti-CD38-
Antikörper ist, und die während der letzten Therapie
eine Krankheitsprogression zeigten. Gegenanzeigen:
Überempfindlichkeit gegen den Wirkstoff oder einen der
in der Fachinformation Abschnitt 6.1 genannten sonstigen
Bestandteile. Inhaber der Zulassung: GlaxoSmithKline
(Ireland) Limited 12 Riverwalk, Citywest Business Campus,
Dublin 24, Irland.
Rezeptpflicht/Apothekenpflicht: Rezept-und
apothekenpflichtig, wiederholte Abgabe verboten.
INDICATION Zulassungsnummer: EU/1/20/1474/001. Dieses
Arzneimittel unterliegt einer zusätzlichen Überwachung.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult Dies ermöglicht eine schnelle Identifizierung neuer
patients, who have received at least four prior therapies and whose disease is refractory Erkenntnisse über die Sicherheit. Angehörige von
to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 Gesundheitsberufen sind aufgefordert, jeden
monoclonal antibody, and who have demonstrated disease progression on the Verdachtsfall einer Nebenwirkung zu melden. Hinweise
last therapy.1 zur Meldung von Nebenwirkungen, siehe Fachinformation
Abschnitt 4.8. Weitere Angaben zu Warnhinweisen
Dosage Information and Method of Administration: The recommended dose for und Vorsichtsmaßnahmen für die Anwendung,
BLENREP is 2.5 mg/kg body weight (bw) administered as an intravenous infusion Wechselwirkungen mit anderen Arzneimitteln
every 3 weeks. und sonstigen Wechselwirkungen, Fertilität,
Schwangerschaft und Stillzeit und Nebenwirkungen
Selection of clinically relevant safety information for BLENREP: entnehmen Sie bitte der veröffentlichten
Contraindications: Hypersensitivity to the active substance or any of the other Fachinformation.
ingredients listed in the SmPC Section 6.1.
Ausführliche Informationen zu diesem Arzneimittel sind
Warnings: Corneal adverse reactions, thrombocytopenia, infusion-related reactions,
auf den Internetseiten der Europäischen Arzneimittel-
sodium, traceability.
Agentur http://www.ema.europa.eu/ verfügbar.
Adverse Reactions: The most common adverse reactions were keratopathy and
thrombocytopenia. The most commonly reported serious adverse reactions were
pneumonia, pyrexia, and infusion-related reactions. Stand der Fachkurzinformation: 08.2020
For a complete listing of contraindications, warnings, and adverse reactions, see
the SmPC.
Any suspected adverse reactions that occur in patients must be reported to the Austrian
Federal Office for Safety in Health Care/Austrian Medicines and Medical Devices Agency
in accordance with the national reporting system for spontaneous reports. You can also
report this information by contacting our pharmacovigilance department by phone under
+43(1)97075-0 or in writing at WW.GSKAEReportingEMEA@gsk.com
ADC=antibody-drug conjugate; BCMA=B-cell maturation antigen; RRMM=relapsed/refractory
multiple myeloma.
Reference: 1. BLENREP (belantamab mafodotin) Summary of Product Characteristics.
Trademarks are property of their respective owners.
©2021 GSK or licensor.
Made for This Moment
PM-GBL-BLM-ADVT-210001 August 2021Program
OAB = Oral Abstract
Presentation
P = Thursday and Friday
Poster AbstractDaily Program Schedule
All times listed and events, including virtual-only sessions, are
being held in Central European Standard Time.
Wednesday, September 8th
09:00-10:00 OPENING SESSION
Opening Ceremonies and Welcome to IMW18 Organizers of 18th IMW
IMS President Address Nikhil Munshi
PLENARY SESSIONS
10:00-11:15 Precursor Conditions
Session Chairs: Mario Boccadoro/Sigurdur Kristinson
Genomic evolution - germinal B cell to MGUS/SMM/MM Brian Walker
Role of the immune Microenvironment in the Madhav Dhodapkar
journey to MGUS/SMM/MM
Molecular Timing of Initiation Niels Weinhold
Risk factors for MGUS/SMM progression Vincent Rajkumar
Management of Smoldering Myeloma Marivi Mateos
Should we screen for precursor conditions? Irene Ghobrial
11:15-12:30 Molecular dissection of myeloma
Session Chairs: Leif Bergsagel/Masood Shammas
Clonal diversity in Myeloma Mehmet Samur
Transcriptome Jill Corre
Epigenomic Wee Joo Chng
Microbiome Leif Bergsagel
Proteomics Arun Wiita
Metabolomics Rafael Fonseca
12:30-13:30 EXPOSITION AND LUNCH
18TH INTERNATIONAL MYELOMA WORKSHOP | 23Daily Program Schedule (cont.)
PLENARY SESSION
13:30-14:30 Multiple Myeloma Diagnosis
Session Chairs: Shaji Kumar/P. Joy Ho
Diagnostic criteria and work-up in 2021 Shaji Kumar
How should we define standard and high risk MM in 2022? Herve Avet-Loiseau
Role of imaging in diagnosis and response assessment Elena Zamagni
Circulating tumor cells and tumor DNA for response Bruno Paiva
assessment
Mass-spec to monitor the treatment response Dave Murray
Assessment of patient frailty and functional status Alessandra Larocca
14:30-15:15 IMS AWARDS
Bart Barlogie/Ken Anderson Young Investigator Award Presentation
Waldenstrom Award Presentation and Lecture
15:15-15:45 EXPOSITION AND BREAK
16:45-17:45 HOT TOPICS IN MYELOMA
In 2021, what is the unmet need in Myeloma? Regulatory considerations
Session Moderators: Nikhil Munshi/Jesús San-Miguel
FDA perspective Nicole Gormley
EMA perspective
I square effort updates and future directions Brian Durie
17:45-19:15 WELCOME RECEPTION IN EXPOSITION AREA
Thursday, September 9th
08:00-09:00 MEET THE EXPERTS VI R T U A L O NL Y
Extramedullary disease Cyrille Touzeau
Plasma cell leukemia Artur Jurczyszyn/Ravi Vij
Management of Monoclonal gammopathy Javier de la Rubia/
of renal significance Moshe Gatt
Management of Monoclonal gammopathy Laura Rosiñol/
of clinical significance Ajay Nooka
Special forms of MM: macrofocal, non-secretory MM Stathis Kastritis/
Jacob Laubach
24 | 18TH INTERNATIONAL MYELOMA WORKSHOPManagement of LC Amyloidosis Vaishali Sanchorawala/
Eli Muchtar
Management of Waldeström’s Macroglobulinemia Ramón García-Sanz/
Prashant Kapoor
Management of POEMS Angela Dispenzieri
Allogeneic Stem Cell Transplantion in MM Charlotte Pawlyn
08:00-09:00 CAREER DEVELOPMENT WORKSHOP VI R T U A L O NL Y
Writing successful grants Suzanne Lentzsch/
Diane Jelinek
09:00-09:30 OPENING SESSION
Novel therapies for myeloma Kenneth Anderson
09:30-10:30 PLENARY SESSION
Newly diagnosed Multiple Myeloma: Current Treatment Approaches
Session Chair: María-Victoria Mateos
Treatment of Newly Diagnosed Myeloma Transplant Philippe Moreau
Eligible: what is the optimal induction?
ASCT in NDMM transplant eligible Michele Cavo
Consolidation Strategies for MM Pieter Sonneveld
Maintenance Strategies for MM Hartmut Goldschmidt
Treatment of Newly Diagnosed Myeloma Theirry Facon
Non-Transplant Eligible
10:30-11:45 ORAL ABSTRACT SESSIONS
Session Chairs: Lugui Qiu/Ed Stadtmauer
OAB1: Overall Survival and Progression-free Survival by Philippe Moreau
Treatment Duration With Daratumumab + Lenalidomide/
Dexamethasone in Transplant-ineligible Newly
Diagnosed Multiple Myeloma: Phase 3 MAIA Study
OAB2: Daratumumab improves depth of response and Andrzej Jakubowiak
progression free survival in transplant-ineligible,
high-risk, newly diagnosed multiple myeloma (NDMM)
OAB3: CARDAMON:Carfilzomib (K) maintenance Rakesh Popat
following Autologous Stem Cell Transplant (ASCT) or
carfilzomib-cyclophosphamide-dexamethasone (KCd)
consolidation for newly diagnosed (NDTE) multiple
myeloma (MM)
18TH INTERNATIONAL MYELOMA WORKSHOP | 25Daily Program Schedule (cont.)
OAB4: Carfilzomib-Based Induction/Consolidation With Roberto Mina
or Without Autologous Transplant and Lenalidomide (R)
or Carfilzomib-Lenalidomide (KR) Maintenance: Efficacy
in High-Risk Patients of the FORTE study
OAB5: Update of Safety and Efficacy of Isatuximab Enrique Ocio
Short-Duration Fixed-Volume Infusion Plus Bortezomib,
Lenalidomide, and Dexamethasone Combined Therapy
for NDMM Ineligible/With No Immediate Intent for ASCT
Session Chairs: Paola Neri/Dharminder Chauhan/Niklas Zojer
OAB6: A novel algorithm to identify, characterize and Vincenza Solli
define the prognostic impact of complex catastrophic
events in Multiple Myeloma
OAB7: Single-cell multiomic analysis identifies regulatory Alexandra Poos
programs in relapsed/refractory multiple myeloma
OAB8: Identification of High-Risk Multiple Myeloma with Davine Hofste op
a Plasma Cell Leukemia-Like Transcriptomic Profile Bruinink
OAB9: Genome-Wide CRISPR interference Screen Eugenio Morelli
Identifies RNA Regulator of Lipogenesis (RROL) as a
Leading LncRNA Dependency in Multiple Myeloma
OAB10: Gain(1q) promotes mitochondrial oxidative Rodger Tiedemann
phosphorylation and suppresses interferon response
and tumor immunity in multiple myeloma and other
human cancers
OAB11: Clonal phylogeny and evolution of critical Yuting Yan
cytogenetic aberrations in multiple myeloma at
single cell level
PLENARY SESSION
11:45-12:45 Management of relapsed/refractory MM patients
Session Chairs: Meral Beksac/Gösta Gahrton
Approach to first relapse Meletios-Athanassios
Dimopoulos
Management of triple refractory patients Bob Orlowski
Role of immunotherapies for relapsed MM, Saad Usmani
when and which?
Personalized treatment of relapsed MM: genomics? Marc Raab
12:45-13:45 EXPOSITION AND LUNCH
26 | 18TH INTERNATIONAL MYELOMA WORKSHOP15:15-16:30 ORAL ABSTRACT SESSIONS
Session Chairs: Natalie Callander/Merav Leiba
OAB12: Depth of response and MRD in newly diagnosed Martin Kaiser
ultra high-risk myeloma and plasma cell leukemia
treated with Dara-CVRd and V-MEL ASCT: results of the
molecularly stratified UK OPTIMUM/MUKnine trial
OAB13: Iberdomide (IBER) in combination with Sagar Lonial
dexamethasone (DEX) and daratumumab (DARA),
bortezomib (BORT), or carfilzomib (CFZ) in patients (pts)
with relapsed/refractory multiple myeloma (RRMM)
OAB14: Newly diagnosed Multiple Myeloma patients with A. Cathelijne Fokkema
high levels of circulating tumor cells are distinguished
by increased bone marrow plasma cell proliferation
OAB15: Minimal residual disease following autologous Ruth De Tute
stem cell transplant for myeloma patients in the
Myeloma XI trial: prognostic significance and the
impact of lenalidomide maintenance and molecular risk
OAB16: Treatment pathways for patients with multiple Aurore Perrot
myeloma: a real-life study based on the French
National Claim database from 2014 to 2019
Session Chairs: Enrique Ocio/Annemeik Brojil
OAB17: Attenuation of T cell cytotoxicity mediated by Pooja Shah
CD200 expression on multiple myeloma cells
OAB18: A BCL2L1 armoured BCMA-targeting CAR T cells Nizar Bahlis
to overcome exhaustion and enhance persistence
in multiple myeloma
OAB19: CRISPR screens with single-cell transcriptome Sara Gandolfi
readout reveal potential mechanisms of response to
natural killer cell treatment in multiple myeloma
OAB20: The Role of Checkpoint inhibitor PD-1H/VISTA Suzanne Lentzsch
in Multiple Myeloma Bone Disease
OAB21: BCMA-specific ADC MEDI2228 and Yu-Tzu Tai
Daratumumab induce synergistic myeloma cytotoxicity
via enhanced IFN-driven innate immune responses and
expression of CD38 and NKG2D ligands
OAB22: Monoallelic Deletion of BCMA Locus is a Mehmet Samur
Frequent Feature in MM and is Associated with
Increased Genomic Loss
16:30-17:00 EXPOSITION AND BREAK
18TH INTERNATIONAL MYELOMA WORKSHOP | 27Daily Program Schedule (cont.)
18:00-19:00 POSTER SESSION
Friday, September 10th
08:00-09:00 MEET THE EXPERTS VI RTUAL ONLY
Covid-19 and MM Wenming Chen/
Sarah Holstein
Vaccination and prophylaxis in Myeloma Laurent Garderet
Management of cellular therapy-related toxicities Krina Patel
Bone disease control in Myeloma Matthew Drake
Management of MM patients with renal impairment Ruben Niesvizky
Which is the ideal patient to be refered for CAR-T Melissa Alsina/
vs bi-specific vs ADC? Sham Mailankody
Racial disparity and monoclonal gammopathies Craig Cole
08:00-09:00 CAREER DEVELOPMENT WORKSHOP VI RTUA L ONLY
Developing your first clinical trial Simon Harrison/
Jean-Luc Harousseau
09:00-09:30 OPENING SESSION
Future of myeloma treatment Jesus San Miguel
09:30-10:30 IMS/EHA SYMPOSIUM
Immune Therapies: A game changer for Hematological Malignancies
Chairs: Kenneth Anderson/Pieter Sonneveld
New immune therapies for lymphoma Gilles Salles
New immune therapies for CLL John Gribben
10:30-11:45 ORAL ABSTRACT SESSIONS
Session Chairs: Michael O’Dwyer
OAB23: Efficacy and safety of ciltacabtagene autoleucel, Adam Cohen
a BCMA-directed CAR-T cell therapy, in patients with
progressive multiple myeloma after 1–3 prior lines of
therapy: Initial results from CARTITUDE-2
OAB24: Updated results from CARTITUDE-1: Sundar Jagannath
Ciltacabtagene autoleucel, a B-cell maturation antigen–
directed chimeric antigen receptor T (CAR-T) cell therapy,
in relapsed/refractory multiple myeloma (RRMM)
28 | 18TH INTERNATIONAL MYELOMA WORKSHOPOAB25: Talquetamab, a G protein-coupled receptor Niels van de Donk
family C group 5 member D (GPRC5D)×CD3 bispecific,
antibody in relapsed/refractory multiple myeloma (RRMM):
Updated results of a phase 1, first-in-human study
OAB26: MagnetisMM-1 study of elranatamab Bhagirathbhai Dholaria
(PF-06863135), a B-cell maturation antigen (BCMA)
targeted CD3-engaging bispecific molecule, for patients
(pts) with relapsed or refractory multiple myeloma (MM)
OAB27: Idecabtagene vicleucel (ide-cel, bb2121), a Larry Anderson
BCMA-directed CAR T-cell therapy, for the treatment of
patients with relapsed and refractory multiple myeloma
(RRMM): updated results from KarMMa
Session Chairs: Ruth De Tute/Aurore Perrot/Tomas Jelinek
OAB28: FAM46C-Dependent Tuning of Endoplasmic Enrico Milan
Reticulum Capacity in Multiple Myeloma
OAB29: Bone marrow adipocytes induce metabolic Cristina Panaroni
reprogramming of multiple myeloma cells
OAB30: Combined targeting of distinct c-Myc and Judith Lind
JunB transcriptional programs induces synergistic
anti-myeloma activity
OAB31: Circular RNA protein tyrosine kinase 2 promotes Fan Zhou
cell proliferation, migration and suppresses apoptosis
via activating microRNA-638 mediated MEK/ERK,
WNT/β-catenin signaling pathways in myeloma
OAB32: Targeting GCK in RAS-mutant multiple myeloma Suzanne Lentzsch
offer a promising therapeutic approach
OAB33: Loss-of-function of GABARAP drives tumor Annamaria Gulla
resistance to bortezomib-induced immunogenic cell
death in multiple myeloma
PLENARY SESSION
11:45-12:45 Other Plasma Cell Disorders
Session Chairs: Giampolo Merlini/Jorge Castillo
Current strategies for AL patients Giovanni Palladini
What are the novel approaches in WM? Steve Treon
Monoclonal gammopathy of clinical significance Joan Blade
Monclonal gammopathy of renal significance Nelson Leung
12:45-13:45 EXPOSITION, POSTER SESSION AND LUNCH
18TH INTERNATIONAL MYELOMA WORKSHOP | 29Daily Program Schedule (cont.)
15:15-16:30 ORAL ABSTRACT SESSIONS
Session Chairs: Jens Hillengass/Angelo Maiolino
OAB34: Evaluating the Impact of Cytogenetic Abnormalities Shaji Kumar
on Treatment Outcomes in Patients with AL Amyloidosis:
Subanalyses From the ANDROMEDA Study
OAB35: Minimally invasive profiling of tumor and immune Rosalinda Termini
cells to stratify risk in smoldering multiple myeloma
(SMM): the iMMunocell study
OAB36: Graded Renal Response Criteria and Revised Eli Muchtar
Renal Progression Criteria for Light chain (AL) Amyloidosis
OAB37: Assessing the prognostic utility of the Mayo 2018 Alyssa Visram
and IMWG 2020 smoldering multiple myeloma risk
stratification scores applied post diagnosis
OAB38: Graded Cardiac Response Criteria for AL: Eli Muchtar
Amyloidosis The Impact of Depth of Cardiac Response
on Survival
Session Chairs: Constantine Mitsiades/Virgina Abello
OAB39: Distinct immunoglobulin heavy-chain variable Yuting Yan
gene repertoire and its clinical relevance in Waldenström
macroglobulinemia/lymphoplasmacytic lymphoma
OAB40: Clonal hematopoiesis is associated with Sabrin Tahri
increased risk of progression of asymptomatic
Waldenström Macroglobulinemia
OAB41: Epithelial-mesenchymal-transition regulated by Antonio Solimando
Junctional Adhesion Molecule-A (JAM-A) associates with
aggressive extramedullary multiple myeloma disease.
OAB42: Targeting Free Light Chain Secretion via Maria Moscvin
Botulinum Neurotoxin is a Novel Therapeutic Strategy
in AL amyloidosis by Inducing a Terminal Unfolded
Protein Response
OAB43: Progression and probability of progression Anil Aktas-Samur
are driven by different genomic features in precursor
conditions in myeloma
OAB44: Anti-CD38 nanobodies as theranostic agents Jo Caers
for multiple myeloma
16:30-17:00 EXPOSITION AND BREAK
30 | 18TH INTERNATIONAL MYELOMA WORKSHOP18:00-19:15 HOT TOPICS IN MYELOMA
Covid-19 in MM: what we have learnt?
Session Moderators: Karthik Ramasamy/Douglas Joshua
OAB45: COVID-19 Vaccine Responsiveness in Patients with Andrew Branagan
Multiple Myeloma and Waldenström Macroglobulinemia
OAB46: COVID-19 infection in multiple myeloma Jakub Radocha
patients – retrospective analysis of 371 Czech patients
OAB47: Plasma cell disorder patients are left vulnerable Wei Yee Chan
after one dose of the BNT162b2 mRNA or the
ChAdOx-nCOV-19 COVID-19 vaccines
OAB48: Suboptimal humoral immune response to Oliver Van Oekelen
SARS-CoV-2 mRNA vaccination in myeloma patients is
associated with anti-CD38 mAb and BCMA-targeted
treatment.
OAB49: Poor Post-vaccination Anti-SARS-CoV-2-Antibody Susanne Ghandili
Response in Patients with Multiple Myeloma
correlates with low CD19+ B-lymphocyte count and
Anti-CD38 Treatment
What have we leaned? Evangelos Terpos
Panelists: Joaquín Martinez, Pankaj Malhotra,
Heinz Ludwig, Juan Du, Dorotea Fant’l, Jakub Radocha
20:00-23:00 IMS CULTURAL CELEBRATION AND AWARDS PRESENTATION
Saturday, September 11, 2021
08:00-09:00 MEET THE EXPERTS VI RTUAL ONLY
Animal models for myeloma Karin Vanderkerkin/
Marta Chesi
Genomic techniques Mark Bustoros/
Ruben Carrasco
Approaches to proteomic analysis Saloman Manier/
Naomi Puig
Primary sample processing and enrichment techniques Jonathan Keats/
Daniel Auclair
Single cell approaches Manoj Bhasin/Jens Lohr
Assessing the immune system Hearn Cho/Tax Kourelis
Metabolomics techniques in MM Malathy Shanmugam/
Wilson Gonsalves
ChIP in Myeloma Adam Sperling
18TH INTERNATIONAL MYELOMA WORKSHOP | 31Daily Program Schedule (cont.)
08:00-09:00 CAREER DEVELOPMENT WORKSHOP VI R T U A L O NL Y
Setting up your laboratory research program Rodger Tiedeman/
Larry Boise
10:00-11:15 ORAL ABSTRACT SESSIONS
Session Chairs: Jae Hoon Lee/Elizabet Manasanach
OAB50: OCEAN (OP-103): A Phase 3, Randomized, Global, Fredrik Schjesvold
Head-to-Head Comparison Study of Melflufen and
Dexamethasone (Dex) Versus Pomalidomide (Pom) and
Dex in Relapsed Refractory Multiple Myeloma (RRMM)
OAB51: Daratumumab, Carfilzomib, Lenalidomide and Luciano J. Costa
Dexamethasone (Dara-KRd), Autologous Transplantation
and MRD Response-Adapted Treatment Duration and
Cessation in Newly Diagnosed Multiple Myeloma (NDMM)
OAB52: Impact of chromosome 1 abnormalities on newly Prashant Kapoor
diagnosed multiple myeloma treated with proteasome
inhibitor, immunomodulatory drug, and dexamethasone:
analysis from the ENDURANCE ECOG-ACRIN E1A11 trial
OAB53: Clinical outcomes of relapsed/refractory multiple Oliver Van Oekelen
myeloma patients after BCMA-targeted CAR T therapy.
OAB54: Single-cell RNA-sequencing identifies immune Romanos
biomarkers of response to immunotherapy in patients Sklavenitis-Pistofidis
with high-risk Smoldering Myeloma
Session Chairs: Mariateresa Fulciniti/Nicolo Bolli/Maria-Theresa Krauth
OAB55: Gain and Amplification of 1q Induce Mattia D’Agostino
Transcriptome Deregulation and Worsen the Outcome
of Newly Diagnosed Multiple Myeloma Patients
OAB56: A machine learning model based on tumor and Camila Guerrero
immune biomarkers to predict undetectable measurable
residual disease (MRD) in transplant-eligible multiple
myeloma (MM)
OAB57: Temporal-weight estimation of the copy number Andrea Poletti
alterations of 1384 multiple myeloma patients defines
an ancestrality index impacting patient survival
OAB58: Predictive relevance of sustained MRD negativity Angelo Belotti
and of early loss of MRD negativity during maintenance
therapy after transplant in newly diagnosed Multiple
Myeloma patients
OAB59: Towards a comprehensive multimodal minimal Marina Martello
residual disease assessment in multiple myeloma:
the role of circulating cell-free DNA to define the extent
of disease spreading
32 | 18TH INTERNATIONAL MYELOMA WORKSHOPYou can also read
